NCI | Technology Transfer

Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Hungary
17753704.0
Filed on 2017-02-14

Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Greece
17753704.0
Filed on 2017-02-14

Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Denmark
17753704.0
Filed on 2017-02-14

Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Germany
17753704.0
Filed on 2017-02-14

Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Czech Republic
17753704.0
Filed on 2017-02-14

Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Switzerland
17753704.0
Filed on 2017-02-14

Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Belgium
17753704.0
Filed on 2017-02-14

Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab

Austria
17753704.0
Filed on 2017-02-14

ADAM17 BINDING MOLECULES AND USES THEREOF

Read more about ADAM17 BINDING MOLECULES AND USES THEREOF

European Patent
20769619.6
Filed on 2020-03-07

Chimeric Antigen Receptors Containing Glypican 2 Binding Domains

Read more about Chimeric Antigen Receptors Containing Glypican 2 Binding Domains

Japan
2022-503413
Filed on 2020-07-17

Subscribe to NCI